Pharmacogenetics of hypoglycemic agents
Despite the increase in the number of hypoglycemic agents, 35%–40% of patients with diabetes are unable to achieve adequate glycemic control. One of the reasons is the genetic heterogeneity of diabetes mellitus, requiring different treatment approaches; however, the individual metabolic features and...
Guardado en:
Autores principales: | Irina Vladimirovna Kononenko, Aleksandr Yuryevich Mayorov, Ekaterina Olegovna Koksharova, Marina Vladimirovna Shestakova |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/82f953229ed34cbea404d841af9850cd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Consensus statement by a panel of experts of the Russian Association of Endocrinologists (RAE) on initiation and intensificationof hypoglycemic therapy for type 2 diabetes mellitus
por: Ivan Ivanovich Dedov, et al.
Publicado: (2011) -
EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
por: Gagik Radikovich Galstyan
Publicado: (2013) -
Hypoglycemic therapy in patients on hemodialysis and peritoneal dialysis
por: Irina Arkad'evna Bondar', et al.
Publicado: (2010) -
Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
por: Marina V. Shestakova, et al.
Publicado: (2017) -
Cardiovascular implications of modern algorithm of hypoglycemic therapy: ?Florentine hypothesis?
por: Andrey Alexeevich Aleksandrov, et al.
Publicado: (2010)